Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Susan H EshlemanJessica M FogelEstelle Piwowar-ManningGordon ChauVanessa CummingsYaw AgyeiPaul RichardsonPhilip SullivanCasey D HainesLane R BushmanChristos PetropoulosDeborah PersaudRyan KofronCraig W HendrixPeter L AndersonJennifer FarriorJohn MellorsAdeola AdeyeyeAlex RinehartMarty St ClairSusan FordJames F RooneyCarrie-Anne MathewPortia HunidzariraElizabeth SpoonerJuliet MpendoGonasagrie NairMyron S CohenJames P HughesMina HosseinipourBrett HanscomSinead Delany-MoretlweMark A MarzinkePublished in: The Journal of infectious diseases (2022)
Almost all incident HIV infections occurred in the setting of unquantifiable or low drug concentrations. CAB resistance was not detected. Transmitted nonnucleoside reverse-transcriptase inhibitor resistance was common; 1 woman may have acquired nucleoside reverse-transcriptase inhibitor resistance from study drug exposure.